Sometimes breast cancer can emerge between routine mammograms. Five years after recovery, one patient's story reinforces the ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Shorter breastfeeding duration and younger age at first birth are known risk factors for triple negative breast cancer and vary by race.

Triple-negative breast cancer (TNBC), a subgroup that lacks expression of hormone receptors and HER2, overlaps with basal-like breast cancer (BLBC), a subgroup that expresses cytokeratins and ...

New research presented at ESMO Breast 2025 shows taxane chemotherapy significantly improves one-year survival in advanced ...

An estimated 1 million cases of breast cancer are diagnosed annually worldwide, and of these around 170,000 are triple-negative cases. TNBC is more common in women under 40 and black women.

Tumor-negative breast cancers misclassified as HER2 ... Adjuvant trastuzumab has significantly improved the prognosis of breast cancer patients both in terms of disease-free survival and overall ...

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? Hopefully a new standard of care for the aggressive disease ...

Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary ...